Circio fundamentale forhold (CRNA, tidl. TRVX)

[TekBot]

Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs

Reference is made to the stock exchange announcement published by Targovax ASA
(the “Company”) on 2 March 2022 regarding exercise of options under LTI program,
settlement of RSUs and resolution to increase the share capital.
…

Vis børsmeldingen

Please see the attached notification of trade for board member and primary
insider Robert Burns’ settlement of RSUs in the Company.

Notification by Primary Insiders Robert Burns
(02.03.22).pdf (https://mb.cision.com/Public/17093/3517863/a2b59a550a2de5b4.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Financial calendar

Financial calendar for Targovax ASA

FINANCIAL YEAR 2021
…

Vis børsmeldingen

09.03.2022 - Annual Report

FINANCIAL YEAR 2022

18.08.2022 - Half-yearly Report
20.04.2022 - Annual General Meeting

12.05.2022 - Quarterly Report - Q1
03.11.2022 - Quarterly Report - Q3
16.02.2023 - Quarterly Report - Q4

This information is published pursuant to the requirements set out in the Continuing obligations.

Kilde

[Bookforest]

Någon som har Dnb:s senaste analys och vill dela med sig?

[TekBot]

Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULONT

· The parties have entered into a collaboration agreement to develop Targovax´s
TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON
adjuvant technology
…

Vis børsmeldingen

· The agreement may be extended into an exclusive commercial partnership for
KRAS vaccination if the combination proves effective in exploratory clinical
studies

Oslo, Norway, 07 March 2022 - Targovax ASA (OSE: TRVX), a clinical-stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, and Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate
immune response to cancers and infections, today announce that they have entered
into a clinical collaboration and supply agreement to combine Targovax’s TG
mutant KRAS cancer vaccines with Agenus´s clinically validated and FDA approved
QS-21 STIMULON adjuvant.

The TG vaccines are peptide mixtures designed to elicit polyvalent immune
responses against the most frequent mutations in the RAS gene family, which
drive up to 30% of all cancers. TG01 has shown promise in phase 1/2 clinical
trials, and Targovax has recently been awarded two prestigious research grants
providing up to NOK 18m in funding to advance the TG program. Cancer vaccines
require combination with an adjuvant in order to stimulate antigen processing
and T-cell priming, and Targovax has selected QS-21 STIMULON as the adjuvant of
choice for continued clinical development.

QS-21 STIMULON is a purified, natural saponin proprietary to Agenus. It has
been widely studied in over 120 clinical trials and consistently demonstrated
powerful antibody and cell-mediated immune responses as well as a favorable
safety profile. QS-21 STIMULON is a critical component of multiple vaccines,
including GSK’s FDA approved Shingrix® shingles vaccine with protection
exceeding 9 years, and the world’s first malaria vaccine MosquirixT.

Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and
scientific support for up to three initial TG01 clinical trials in different
cancer indications. If the clinical results meet certain pre-specified
performance targets, the collaboration will be extended into an exclusive
pivotal development and commercialization agreement where Agenus will be
entitled to tiered double-digit royalties on future TG vaccine sales.

Dr. Garo H. Armen, Chief Executive Officer of Agenus Inc., said: “We look
forward to collaborating with Targovax to extend the benefit of QS-21 STIMULON
to new patient populations such as those harboring KRAS-mutated cancers. It
highlights the broad applicability of our QS-21 STIMULON technology and could
unlock a sizeable commercial opportunity in KRAS-mutated cancers.”

Dr. Erik Digman Wiklund, Chief Executive Officer of Targovax ASA, added: “QS-21
STIMULON is arguably the most clinically and commercially successful FDA
approved adjuvant for protein- and peptide-based vaccines, and has proven highly
effective in eliciting immune responses. We expect that this unique adjuvant
will further enhance the efficacy of our TG01 and TG02 products, and see it as a
critical component of our development strategy as we prepare to bring the TG
vaccines back into the clinic in multiple mutant KRAS cancers.”

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and
development of therapies that engage the body’s immune system to fight cancer.
The Company’s vision is to expand the patient populations benefiting from cancer
immunotherapy by pursuing combination approaches that leverage a broad
repertoire of antibody therapeutics, adoptive cell therapies (through its
subsidiary MiNK Therapeutics), adjuvants, and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity to support
clinical programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle @agenus_bio.
Information that may be important to investors will be routinely posted on our
website and Twitter.

Agenus Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to
the safe harbor provisions of the federal securities laws, including statements
regarding clinical development and regulatory plans and timelines, anticipated
corporate milestones, new clinical data and program updates to be presented.
These forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors section of
our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this press release,
and Agenus undertakes no obligation to update or revise the statements, other
than to the extent required by law. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement.

Contact
Agenus Inc.
Divya Vasudevan, PhD
781-674-4571
divya.vasudevan@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Kilde

[TekBot]

Targovax ASA: GRANT OF SHARE OPTIONS TO NEW CFO

Oslo, 7 March 2022: Reference is made to the announcement made by Targovax ASA
(“Targovax” or the “Company”) 28 February 2022 regarding the appointment of
Lubor Gaal as the new CFO of the Company.
…

Vis børsmeldingen

The Board of Directors has resolved to grant 300,000 share options in the
Company under the Company’s long term incentive program, each with a strike
price of NOK 1.53, to Lubor Gaal.

Following the grant of the 300,000 share options referred to above, Lubor Gaal
holds nil shares and 300,000 options in the Company.

The options are granted without consideration. Pursuant to the vesting schedule,
25% of the options will vest 12 months after the day of grant (as long as the
option holder is entitled to be part of the option program). Thereafter, 1/36 of
the remaining options will vest each month as long as the option holder is
entitled to be part of the option program, with the first 1/36 vesting 13 months
after the day of grant. The exercise price is equal to the volume weighted
average trading price of the shares of the Company on Oslo Børs on the date of
the grant. Options that have not been exercised will lapse 7 years after the
date of grant.

Please see the attached the notification of trading pertaining to the
abovementioned mandatory notification of trade by primary insider.

Notification by Primary
Insiders_Gaal_Mar21.pdf (https://mb.cision.com/Public/17093/3520223/ad13d8567bce2
376.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[solskimm]

En liten tikkeliste på hva vi kan forvente oppdatering på etterhvert:

• ONCOS 102 plattform med 2x Fast Track Designations og best in class x2

  • Melanoma NewsWeb

    • Studieoppsett
    • Partner for CPI / CTLA-4 inhibitor
    • Første pasient dosert

  • Mesothelioma - ASCO-poster 2022

    • Hva er veien videre?

• TG, Agenus, mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULONT

  • TG indikasjon 1 : RAS mutant multiple myeloma, NewsWeb , 20 pasienter
    • Finansiert via offentlige tilskudd
    • Studieoppsett
    • Første pasient
  • TG indikasjon 2
  • TG indikasjon 3

• Next gen virus preklinisk

• CRNA preklinisk

• Pågående studie i colorectal (samarbeid uten kostnad, i kombinasjon med AstraZeneca, Cancer Research Institute (CRI) og Ludwig Cancer Research)

  • Oppdateres på ASCO 2022

• IOVAXIS Therapeutics, TG01/02, potensiell utlisensieringsavtale for Kina

  • Venter på oppdatering, potensielt 30mill upfront
  • Utvidelse av programmet til resten av verden?

• VALO Therapeutics, oppdatering samarbeid, ONCOS-102,

• OBLIQUE Therapeutics, oppdatering samarbeid, Oncolytic virus w/ mutRAS
  antibody payload

• Leidos checkpoint inhibitor functionality to ONCOS viruses

• Zelluna Immunotherapy, FTO license to intellectual property relating to mutant RAS T cell receptor technology

• Papyrus Therapeutics, ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

  • PYTX-003 Oppdatering H1 23

Er det noe jeg har glemt eller er feil så gi meg beskjed så oppdaterer jeg

*Edit: Oppdatert med ASCO-postere på Meso og colorectal.
*Edit 2: oppdatert med TG-indikasjon 1 av 3

[TekBot]

Targovax ASA: Registration of share capital increases following exercise of options

Oslo, 8 March 2022: Reference is made to the stock exchange announcement by
Targovax ASA (“Targovax” or the “Company”) on 2 March 2022, regarding the board
of directors’ resolutions to increase the share capital of the Company in
…

Vis børsmeldingen

connection with the exercise of employee options and RSUs.

The share capital increases have today been registered with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret). The Company’s new
share capital is NOK 18,842,242.10, divided into 188,422,421 shares, each with a
par value of NOK 0.10.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Targovax ASA: Poster presentation at the AACR Annual Meeting

Oslo, Norway, 9 March 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that an abstract has been accepted for poster
…

Vis børsmeldingen

presentation at the American Association for Cancer Research (AACR) Annual
Meeting.

The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor
micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated
with efficient viral gene expression and strong, sustained activation of immune
-related genes, which may be targets for future combinations of ONCOS-102 and
immune-modulators beyond PD-1/PD-L1 inhibitors.

The abstract has been released on the AACR website today
(Abstracts | AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans). The poster
is scheduled for presentation Monday 11 April 2022 and will be available on
Targovax’s website (https://www.targovax.com/en/oncos-oncolytic-virus
-publications-posters-and-oral-presentations/) after the presentation.

Poster Modulation of immune gene expression by intra-tumoral oncolytic
title: adenovirus ONCOS-102 is associated with clinical response in anti
-PD-1 refractory/resistant melanoma
Date and Monday 11 April 2022, 13:30- 17:00 CDT / 20:30-24:00 CET
time:
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section
31
Session Clinical research excluding trials
category:
Session Immune response to therapies / immune monitoring and clinical
title: correlate
Poster 1983
number:
Presenter: Thomas Birkballe Hansen, VP Research, Targovax

About AACR

The AACR Annual Meeting is the focal point of the cancer research community,
where scientists, clinicians, other health care professionals, survivors,
patients, and advocates gather to share the latest advances in cancer science
and medicine. From population science and prevention; to cancer biology,
translational, and clinical studies; to survivorship and advocacy; the AACR
Annual Meeting highlights the work of the best minds in cancer research from
institutions all over the world.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Targovax ASA: Annual Report 2021

On 9 March 2022, the Board of Directors of Targovax ASA approved the Company’s
Annual Report, including the financial statements for 2021, which will be
processed at the Company’s annual general meeting on 20 April 2022. Targovax ASA
…

Vis børsmeldingen

also publishes today its annual financial statements in the European Single
Electronic Format (ESEF), which is available as an attachment to this release.

The documents are also available at the Company’s website,
www.targovax.com (Financial Reports – Targovax).

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Targovax - Proposal to implement a drop-down demerger

Lysaker, 14 March 2022: The Board of Directors of Targovax has today, on 14
March 2022, signed a joint demerger and merger plan, respectively, for the
transfer of the operational activities of the Company to its wholly-owned
…

Vis børsmeldingen

subsidiary, Targovax Solution AS.

The transfer is proposed carried out as a “drop-down demerger” where the Company
demergers operations and assets to its subsidiary Athomstart Invest 586 AS.
Immediately after the demerger, Athomstart Invest 586 AS merges with the
Company’s wholly owned subsidiary, Targovax Solution AS, whereby the merger
consideration is issued in the Company and corresponds to the share capital
decrease amount in the Company in connection with the Demerger.

The background for the proposed drop-down demerger is that the Board of
Directors finds it desirable to establish a pure group structure, with separate
operating companies rather than having operations in the listed parent company.

On this basis, the Board of Directors will propose that the Annual General
Meeting to be held on 20 April 2022 approves the demerger and merger plan, with
their respective appendices, both dated 14 March 2022, in addition to adopting
the other corporate resolutions that are required in order to implement the drop
-down demerger.

The demerger plan for the demerger and the merger plan for the merger with their
respective appendices, both dated 14 March 2022, will be available at the
Company’s website www.targovax.com (https://www.targovax.com/en/annual-general
-meeting-2022/) later today pursuant to section 8 of the articles of
association.

The drop-down demerger is expected to be completed during June 2022, subject to
the approval by the Annual General Meeting.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[Altiexiles]

Kan se ut som forberedelse til salg av et lem eller?

[Sjakk]

Tja ikke sak tenker jeg, er vel mer å rydde litt, rett og slett at topp selskapet/holdingen bør være fritt for operasjonell støy, og fokuserer på å drifte datterselskapene sine. Er om det som da ligger i holdingen faktisk er noe som risikerer å bli verdt noe og splittes ut og fusjoneres ned i et datterselskap før det faktisk blir verdt så mye at det blir kostbart å tukle med det (skatteteknisk)

edit: nå fikk jeg litt mer gullpenge vibber. Sjekket struktur, og de har jo ikke en asa holding med underselskaper! så dette er en fisjon ned i et datterselskap… (jada det står i meldingen, jeg innbildte meg at det var fisjonering av noe skrot i ASA/topp selskapet, ut i separat selskap og fusjon inn i et eksisterende datterselskap) Dette blir ny struktur og blodpumpa fikk litt mer fart her

[TekBot]

Notice of Annual General Meeting

The Annual General Meeting of Targovax ASA (the “Company”) will be held at the
Company’s offices at Lysaker, on 20 April 2022 at 16:00 CET.

…

Vis børsmeldingen

Notice of attendance

Notice of attendance must be received no later than 19 April 2022 at 16:00 CET.

Casting of advance votes and submission of proxies must be received no later
than 19 April 2022 at 16:00 CET.

Attached you will find the notice to the General Meeting, including appendices.
The notice and appendices will also be made available on Targovax’ website
General Meetings – Targovax.

TRVX - Notice AGM
20.04.2022.pdf (https://mb.cision.com/Public/17093/3535332/b74086509936d02f.pdf)

For further information, please contact:
Lubor Gaal, CFO
Phone: +34 683 343 811
Email: lubor.gaal@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax ASA: Minutes from the Annual General Meeting

The annual general meeting was held on 20 April 2022 at the Company’s offices at
Vollsveien 19, 1366 Lysaker.

…

Vis børsmeldingen

Please find minutes of the meeting attached:

2022 Targovax ASA AGM
minutes.pdf (https://mb.cision.com/Public/17093/3549223/b330c957fe038019.pdf)

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the “Company”)
on 20 April 2022 (the “AGM”) where election of members to the board of directors
was according to the nomination committee’s proposal. At the same AGM of the
…

Vis børsmeldingen

Company the board of directors was authorized to extend the Company’s restricted
stock unit (“RSU”) program and to issue RSUs to the board members. The RSUs are
non-transferable and each RSU gives the right and obligation to acquire one
share in the Company at a price of NOK 0.10 per share (corresponding to the
nominal value of the shares) subject to satisfaction of the applicable vesting
conditions.

If the board members choose to receive the board remuneration in RSUs they must
elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3
of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the
compensation in cash and 1/3 in RSUs. The number of RSUs is calculated on the
basis of a board remuneration of NOK 525 000 to the chairperson of the board and
NOK 310,000 to the other board members, divided by the market price of the
Company’s shares calculated as the volume weighted average share price for the
10 trading days prior to the AGM being NOK 1.79 per share.

Damian Marron has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 97,765 RSUs to Damian Marron.
Damian Marron holds 141,753 RSUs, no options and no shares in the Company.

Eva-Lotta Allan has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 57,728 RSUs to Eva-Lotta Allan.
Eva-Lotta Allan holds 98,539 RSUs, no options and 71,368 shares in the Company.

Diane Mellett has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 57,728 RSUs to Diane Mellett.
Diane Mellett holds 115,949 RSUs, no options and 96,029 shares in the Company.

Sonia Quaratino has resolved to receive 2/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 115,456 RSUs to Sonia
Quaratino. Sonia Quaratino holds 138,178 RSUs, no options and no shares in the
Company.

Thomas Falck has resolved to receive 2/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 115,456 RSUs to Thomas Falck.
Thomas Falck holds 115,456 RSUs, no options and no shares in the Company.

Raphael Clynes has resolved to receive 2/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 115,456 RSUs to Raphael Clynes.
Raphael Clynes holds 115,456 RSUs, no options and no shares in the Company.

Notification by Primary Insiders_Marron AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/bac1d8a7e99b746c.pdf)

Notification by Primary Insiders_Falck AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/b03e31814e690d85.pdf)

Notification by Primary Insiders_Allan AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/a4078141496ec9f6.pdf)

Notification by Primary Insiders_Quaratino AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/900038e2353c883f.pdf)

Notification by Primary Insiders_Mellett AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/97693b9b7dcb19b1.pdf)

Notification by Primary Insiders_Clynes AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/9096bb0e6944b320.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[Frs2904]

Hvorfor velger 3 av 6 styremedlemmer å ta honoraret i 1/3 aksjer og resten kontanter. Ingen av styremedlemmene valgte 100 % aksjer? Dette gir et tydelig signal om at optimismen ikke er på topp.

[Frs2904]

Alle har vel sin vanlige jobb - styrevervene er vel stort sett tilleggsinntekt? Når de som sitter nærmest selskapet ikke satser mer, så sier det vel alt. Gir et lite tillitsvekkende signal til markedet. Det er tross alt de som sitter nærmest informasjonen.

[Altiexiles]

@Frs2904

Når de som sitter nærmest selskapet ikke satser mer, så sier det vel alt.

No må du gi deg det der er direkte misvisende.

[TekBot]

Targovax ASA announces the appointment of two new Board Directors

Oslo, Norway, 21 April 2022 - Targovax ASA (OSE: TRVX) announces that the
General Meeting has elected Dr Raphael Clynes and Mr Thomas Falck as new members
of its Board of Directors.
…

Vis børsmeldingen

Dr Clynes
Dr Clynes is an internationally recognized cellular immunologist and medical
oncologist. Dr Clynes was on the faculty at the Columbia University where he
developed several novel therapeutic approaches in cancer and autoimmunity. Since
joining industry in 2014, Dr Clynes has led clinical immunotherapy development,
including checkpoint inhibtors and novel CD3 bispecifics, at Bristol Myers
Squibb (BMS) and at Xencor, where he is currently VP Translational Biology.

Dr Clynes is an MIT graduate and MSKCC-trained medical oncologist. As a well
-recognized expert in clinical immunology, Dr Clynes has extensive prior
experience as a contributing member of multiple scientific advisory boards in
biopharma and review boards at international research foundations.

Mr Falck
Mr Falck is an experienced CEO, CFO, Board Chair and Non-Executive Director,
Venture Capitalist & Growth Investor with demonstrated success in defining and
delivering profitable growth while undertaking strategic and organizational
change. He has broad experience with Private Equity, Venture Capital, Stock
Listed, Family and Government owned entities.

Mr Falck holds an MBA from The Darden School at the University of Virginia and
is a graduate of the Norwegian Naval Academy and the Norwegian Defence
University College. In addition, Mr Falck has attended Executive Programs at
Singularity University and Harvard Business School.

The Chairman of Board of Directors, Mr Damian Marron says: “We are very pleased
to have attracted both Dr Clynes and Mr Falck as new members of the Board. Dr
Clynes is a world-leading expert in immuno-oncology and his deep expertise in
translational medicine will be instrumental as we push ONCOS-102 forward in the
clinic and build our portfolio of next generation circular RNA pipeline
candidates. Mr Falck is an experienced NED & Board Member, Investor, Advisor &
Tech Executive, and whose strategic insight will be of great value for the
Board.”

Raphael Clynes and Thomas Falck are replacing Per Samuelsson and Johan
Christenson. Targovax expresses the company’s gratitude for the excellent work
both has done as members of the Board over many years.

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[Birgitte]

Dette er feil ressonement. Disse bruker en del av sine løpende inntekter til å investere i selskapet. Det er positivt.